23 results
PRE 14A
VRNA
Verona Pharma Plc
8 Mar 24
Preliminary proxy
4:18pm
services, (ii) total fees as a percentage of total revenue, (iii) conflict of interest policies, (iv) business or personal relationships with members … and does not believe Aon’s work in 2023 raised a conflict of interest. For discussion of the role of compensation consultants in determining executive
8-K
EX-10.1
fro6b6hmf64tq scu8y
2 Jan 24
Strengthens financial flexibility to support the Company’s continued growth
6:02am
424B5
fdnujs2lk5r4yuds2om
11 Aug 22
Prospectus supplement for primary offering
5:09pm
424B5
wep 1grtdq2kvniqv0z
9 Aug 22
Prospectus supplement for primary offering
12:00am
DEF 14A
o99u6nq 2i
19 Mar 21
Definitive proxy
4:02pm
10-K
m9p356
25 Feb 21
Annual report
8:29am
10-K
EX-10.20
rvstz5177v
25 Feb 21
Annual report
8:29am
6-K
EX-1
1u3qfzobazk9
30 Dec 20
Current report (foreign)
4:11pm
6-K
EX-3
97mxuh2t8e jx9wr
12 Nov 20
Current report (foreign)
6:40am
F-1/A
8my021uqu59d95pbz2qm
25 Aug 20
Registration statement (foreign) (amended)
4:06pm
F-1
ushrc4zpb7jffqs
17 Aug 20
Registration statement (foreign)
6:41am
6-K
EX-2
py53sxnz
22 Jul 20
Current report (foreign)
4:05pm
6-K
EX-1
bqlbwq3jpv5qm
22 Jul 20
Current report (foreign)
4:05pm